Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of CS12192 in Healthy Chinese Subjects
NCT05922709Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CS12192 in rheumatoid arthritis (RA) and graft-versus-host disease (GVHD) (10 arms), sponsored by Akeso, Inc. Primary endpoints: Number of Adverse Events (AEs) up to 14 days, Area Under the Curve and 3 more. Started Jul 2023; status: completed.
02
Drugs
CS12192
03
Conditions
rheumatoid arthritis (RA)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05922709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922709.